Joshua Jennings
Stock Analyst at TD Cowen
(2.56)
# 2,183
Out of 5,127 analysts
75
Total ratings
44.93%
Success rate
3.69%
Average return
Main Sectors:
Stocks Rated by Joshua Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $15 | $4.79 | +213.15% | 1 | Dec 10, 2025 | |
| CBLL CeriBell | Maintains: Buy | $36 → $20 | $22.83 | -12.40% | 3 | Nov 5, 2025 | |
| SENS Senseonics Holdings | Maintains: Buy | $25 → $15 | $6.59 | +127.62% | 2 | Nov 5, 2025 | |
| PRCT PROCEPT BioRobotics | Maintains: Buy | $85 → $50 | $33.92 | +47.41% | 4 | Nov 5, 2025 | |
| DXCM DexCom | Maintains: Buy | $100 → $84 | $70.10 | +19.83% | 2 | Oct 31, 2025 | |
| HUMA Humacyte | Maintains: Buy | $5 → $3.5 | $1.20 | +191.67% | 3 | Aug 12, 2025 | |
| AVR Anteris Technologies Global | Initiates: Buy | $15 | $4.95 | +203.03% | 1 | Jan 7, 2025 | |
| PODD Insulet | Maintains: Buy | $264 → $324 | $299.17 | +8.30% | 1 | Jan 3, 2025 | |
| BSX Boston Scientific | Maintains: Buy | $100 → $110 | $98.65 | +11.51% | 7 | Dec 12, 2024 | |
| TMDX TransMedics Group | Maintains: Buy | $175 → $120 | $137.27 | -12.58% | 9 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $1.68 | +2,876.19% | 1 | Oct 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $143 → $119 | $92.67 | +28.41% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $60 | $40.35 | +48.70% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $83 → $80 | $77.07 | +3.80% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $45 | $4.34 | +936.87% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $100 → $70 | $84.83 | -17.48% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $185 | $207.49 | -10.84% | 1 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 | $20.40 | +96.08% | 4 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $400 | $367.75 | +8.77% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $70.01 | -14.30% | 4 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $34 | $22.71 | +49.71% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $18 | $8.21 | +119.24% | 3 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $25 | $19.37 | +29.07% | 1 | Dec 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 | $127.04 | +2.33% | 9 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $5 | $2.60 | +92.31% | 1 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $117 | $99.77 | +17.27% | 3 | May 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $450 | $2.53 | +17,686.56% | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $21.97 | -45.38% | 1 | Sep 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $306 → $275 | $202.71 | +35.66% | 1 | Feb 7, 2020 |
Orchestra BioMed Holdings
Dec 10, 2025
Initiates: Buy
Price Target: $15
Current: $4.79
Upside: +213.15%
CeriBell
Nov 5, 2025
Maintains: Buy
Price Target: $36 → $20
Current: $22.83
Upside: -12.40%
Senseonics Holdings
Nov 5, 2025
Maintains: Buy
Price Target: $25 → $15
Current: $6.59
Upside: +127.62%
PROCEPT BioRobotics
Nov 5, 2025
Maintains: Buy
Price Target: $85 → $50
Current: $33.92
Upside: +47.41%
DexCom
Oct 31, 2025
Maintains: Buy
Price Target: $100 → $84
Current: $70.10
Upside: +19.83%
Humacyte
Aug 12, 2025
Maintains: Buy
Price Target: $5 → $3.5
Current: $1.20
Upside: +191.67%
Anteris Technologies Global
Jan 7, 2025
Initiates: Buy
Price Target: $15
Current: $4.95
Upside: +203.03%
Insulet
Jan 3, 2025
Maintains: Buy
Price Target: $264 → $324
Current: $299.17
Upside: +8.30%
Boston Scientific
Dec 12, 2024
Maintains: Buy
Price Target: $100 → $110
Current: $98.65
Upside: +11.51%
TransMedics Group
Nov 18, 2024
Maintains: Buy
Price Target: $175 → $120
Current: $137.27
Upside: -12.58%
Oct 2, 2024
Initiates: Buy
Price Target: $50
Current: $1.68
Upside: +2,876.19%
Sep 6, 2024
Maintains: Hold
Price Target: $143 → $119
Current: $92.67
Upside: +28.41%
Aug 27, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $40.35
Upside: +48.70%
Aug 13, 2024
Maintains: Hold
Price Target: $83 → $80
Current: $77.07
Upside: +3.80%
Aug 8, 2024
Maintains: Buy
Price Target: $135 → $45
Current: $4.34
Upside: +936.87%
Jul 25, 2024
Downgrades: Hold
Price Target: $100 → $70
Current: $84.83
Upside: -17.48%
Jul 18, 2024
Maintains: Buy
Price Target: $195 → $185
Current: $207.49
Upside: -10.84%
May 10, 2024
Downgrades: Hold
Price Target: $40
Current: $20.40
Upside: +96.08%
Apr 11, 2024
Maintains: Buy
Price Target: $365 → $400
Current: $367.75
Upside: +8.77%
Mar 12, 2024
Maintains: Outperform
Price Target: $50 → $60
Current: $70.01
Upside: -14.30%
Aug 4, 2023
Maintains: Outperform
Price Target: $52 → $34
Current: $22.71
Upside: +49.71%
May 11, 2023
Maintains: Outperform
Price Target: $14 → $18
Current: $8.21
Upside: +119.24%
Dec 30, 2022
Maintains: Outperform
Price Target: $6 → $25
Current: $19.37
Upside: +29.07%
Dec 13, 2022
Maintains: Outperform
Price Target: $130
Current: $127.04
Upside: +2.33%
Nov 11, 2022
Maintains: Outperform
Price Target: $7 → $5
Current: $2.60
Upside: +92.31%
May 27, 2022
Maintains: Outperform
Price Target: $125 → $117
Current: $99.77
Upside: +17.27%
Dec 7, 2021
Initiates: Outperform
Price Target: $450
Current: $2.53
Upside: +17,686.56%
Sep 3, 2020
Initiates: Outperform
Price Target: $12
Current: $21.97
Upside: -45.38%
Feb 7, 2020
Downgrades: Market Perform
Price Target: $306 → $275
Current: $202.71
Upside: +35.66%